Navigation Links
HCM Announces Substantial Growth in 2007
Date:2/26/2008

Attracts new talent to key positions

BURLINGTON, Mass., Feb. 26 /PRNewswire/ -- Hyaluron Contract Manufacturing (HCM), a leading provider of pharmaceutical development services, continued to expand its business in 2007 with revenues increasing greater than 75 percent and staffing increasing greater than 60 percent to support past and anticipated future growth. Additionally, HCM acquired additional space at its Burlington MA facility to expand its analytical chemistry, microbiology and engineering laboratories as well as to provide additional manufacturing capacity.

"We are very proud of our recent growth," Shawn Kinney, president of HCM states. "It's a reflection of our ongoing commitment to continuous improvements and to providing high quality products and services to our customers."

HCM has continued to strengthen its management team with the appointment of Susan McNamara to the newly created position of Director of Quality and Christopher Paolillo to the position of Director of Contract Administration and Legal Affairs and other key hires.

Susan McNamara has over seventeen years of experience in the biotechnology industry, bringing novel recombinant proteins into clinical and commercial production. Before joining HCM, McNamara was Associate Director, QC Microbiology at Wyeth Biotech. Prior to that, McNamara was employed by Fisons Pharmaceuticals and SmithKline.

Christopher Paolillo has over twenty-seven years of experience as corporate counsel and as an attorney in private practice and with the office of Air Force Judge Advocate. He brings to HCM substantial experience in contracts, licensing, intellectual property, and commercial transactions. Prior to HCM, Paolillo was employed by ACI Worldwide (formerly P&H Solutions) as Vice President and Corporate Counsel.

Located in Burlington, MA, HCM has been offering aseptic formulation and filling services to biotechnology and pharmaceutical companies. At
'/>"/>

SOURCE Hyaluron, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NPS Pharmaceuticals Announces Senior Management Changes
2. BSPs New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study
3. Boston Scientific Announces Addition to Clinical Sciences Organization
4. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
7. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
8. Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress
9. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
10. Aton Pharma Announces the Appointment of Dr. Fred Eshelman to Management Board
11. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...hybrid . . . , Fuel economy ratings for the ne...e www.fueleconomy.gov web site, which Oak Ridge ...e U.S. Department of Energy and the U.S. Environme...s on the best fuel economy list are hybrid electri...ay). "This list proves that hybrids have gone main...
(Date:11/5/2009)... 5 DSM Pharmaceutical Products tod...ance with Galenix, Saint Jean D,Illac, France, whe...facturing partner for Galenix commercial products ...aborate on business development opportunities co-m... on the strength of Galenix in drug product develo...
(Date:11/5/2009)...rsday, November 5, 2009 at 4:30 p.m. Eastern Time ...e-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("O... reported unaudited financial results for the thir... and reviewed the Company,s highlights for the thi...ed results reflect the operations of OncoGenex Tec...
(Date:11/5/2009).... 5 Cepheid (Nasdaq: CP...peaking at the following investor conferences, and... Credit Suisse Healthcare Conferen...mber, 2009 at 10 a.m. Mountain Time, ...and, Tuesday, 1 December, 2009 at ...
Breaking Biology Technology:November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2
...o and TEL AVIV, Israel, October 15 ,Simbionix USA ...of a Series,C round of growth capital financing le...nt investor Early Stage Partners and other existin...s who served as the,company,s investment bankers. ... the already rapid growth of its medical simulatio...
... Medical Education Agency Expanding Industry Conne...re,Communications LLC, an independent, full-servic...ring of Todd Weinstein as Vice President, Business...ence in medical education and,publishing as the he...he,served as Manager of Publication Sales at McMah...
..., Oct. 15 The increased emphasis on,safety by reg...medical,product development programs and requires ...ns by Sponsors to respond appropriately. Expertise...sulting organizations. GZP,has already emplaced sy...s,that can lead to adverse regulatory action by th...
Other Biology Technology:Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth 2Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth 3L&M Healthcare Communications LLC Expands Client Services With Executive Team Expansion 2Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services 2Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services 3
(Date:11/6/2009)... Center and the Chinese Academy of Sciences (CAS) ...on Taste and Smell Research. Organized by Monell i...the first international meeting on taste and smell...utive Officer, American Association for the Advanc...e magazine, will open the meeting with a plenary a...
(Date:11/4/2009)...ant to officially endorse green tea as a cancer pr...its protective effects, including results of a new...a journal of the American Association for Cancer R...cer. , Vassiliki Papadimitrakopoulo, M.D., prof...ad and Neck Medical Oncology at the University of ...
(Date:11/4/2009)..., hold the power to help militaries and munitions ...ic waste on test sites. , Compounds known as nit...orld War II and have been used in military munitio...ften used to propel tank shells and act like a mor...d knowledge of their environmentally harmful effec...
Breaking Biology News(10 mins):Monell Center joins with CAS to host Beijing meeting on taste and smell research 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2Genomic research will enable greener cleanup of military explosive test sites 2IMRIS receives FDA clearance for IMRISNV and IMRIScardio 56403 1IMRIS receives FDA clearance for IMRISNV and IMRIScardio 56403 2Cochlear Americas Announces FDA Approval of the Nucleus 28R 29 5 System the Newest and Most Advanced Cochlear Implant System 56401 1Cochlear Americas Announces FDA Approval of the Nucleus 28R 29 5 System the Newest and Most Advanced Cochlear Implant System 56401 2Cochlear Americas Announces FDA Approval of the Nucleus 28R 29 5 System the Newest and Most Advanced Cochlear Implant System 56401 3Cochlear Americas Announces FDA Approval of the Nucleus 28R 29 5 System the Newest and Most Advanced Cochlear Implant System 56401 4New York Giants to Host American Red Cross Blood Drive 56398 1New York Giants to Host American Red Cross Blood Drive 56398 2
...ee of large-scale catastrophes to pursue their dre...epartment of Homeland Security (DHS) is the federa...errorist attacks and making it a more secure place...ough its Science & Technology (S&T) Directorate, w... leads to products, systems and services that help...
...etable oil and other renewable sources are increas...s as a way to reduce fossil fuel dependence and li... led by a biologist at the University of Washingto...rrent biofuel stocks might have exactly the opposi...ublished in the June issue of the journal Conserva...
...t a fundamental building block in the cells of flo...entically, on a separate branch of the evolutionar...s that originated at least 420 million years ago. ...ved from gymnosperms, the group that includes coni... from lycophytes hundreds of millions of years bef...
Other Biology News:DHS, business leaders discuss technology to protect US at Homeland Security conference 2DHS, business leaders discuss technology to protect US at Homeland Security conference 3Some biofuels might do more harm than good to the environment, study finds 2Some biofuels might do more harm than good to the environment, study finds 3When plants 'think' alike 2
Mouse Anti-Human HLA Class II DQ1 7 Monoclonal Antibody, Unconjugated, Clone 4i144 from Abcam
Anti-ASCIZ Antibody, Unconjugated from CHEMICON
Goat Anti-CHMP5 Polyclonal Antibody, Unconjugated from Abcam
Custom Oligo Assay Single Locus 1920 samples from Illumina
Biology Products: